
Cyberattacks could disrupt or delay patient care, making cybersecurity important to protecting patients in health care.

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.
She has a BA in English language and literature from Rutgers University. You can connect with Julia on LinkedIn.

Cyberattacks could disrupt or delay patient care, making cybersecurity important to protecting patients in health care.

Carolina Barnett-Tapia, MD, PhD, discusses the results of the ADAPT OCULUS trial, which found promising results for treating patients with ocular myasthenia gravis.

Data stored in hospitals, clinics, and medical practices make it a prime target for cyberattacks, making security important for continuity of care.

Adopting more automated services could potentially reduce costs across the country as adoption remains stable nationwide.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The results show that semaglutide could be a novel treatment for patients with alcohol use disorder moving forward.

The new work requirements for Medicaid eligibility, included in the One Big Beautiful Bill Act, will officially be required in January 2027.

Education on colorectal cancer symptoms and screening can help to prevent advancing disease in a cancer that is seeing increased incidence in younger adults.

Patients with advanced glaucoma had better outcomes when treated with trabeculectomy rather than using medication first.

A multimodal AI approach could highlight areas in the brain that were associated with cognitive worsening in patients with MS.

Speakers at the NAACOS Spring 2026 Conference illustrated means of using technology in value-based care to implement preventive medicine.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Cemdisiran offers lower treatment burden for patients living with generalized myasthenia gravis, only needing to be taken every 3 months.

The Merit-Based Incentive Payment System (MIPS) measure excluded nearly half of all patients undergoing surgery, which could affect surgeon performance.

The 5-year prediction of MS progression, defined by clinical and objective measurements, was possible with 2 machine learning tools.

Tuan Vu, MD, explains the results of the NIMBLE trial, whose results will be presented at the American Academy of Neurology conference.

Patients with prescriptions that were initially rejected through prior authorization had more difficulty obtaining the treatment.

World Hemophilia Day spotlights the rare blood disorder that prevents the blood from clotting and can be dangerous when left untreated.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The expiration of subsides for health coverage starting in 2026 has left millions facing higher premiums with little notice.

Patients who were treatment naive or had switched to rituximab saw short-term results of reduced disease activity in multiple sclerosis.

The increased costs of premiums after the expiration of enhanced subsidies have led to an increased percentage of those not able to make their payments.

New results show that reproxalap did not cause any serious treatment-related adverse events in patients living with dry eye disease.

Psychological effects of alopecia areata should be looked into in the future for patients who live with the condition.

Both Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scores improved after treatment.

Poor outcomes could be predicted based on the presence of ectopic germinal centers in the thymus in patients with thymoma-associated myasthenia gravis.

Sequential therapy of ranibizumab and a dexamethasone implant improved results in macular edema secondary to non–ischemic retinal vein occlusion.

Despite decreases in therapy use, hospitalizations for multiple sclerosis and neurologist visits were not affected significantly.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Adults can undergo CAR T-cell therapy for relapsed or refractory mantle cell lymphoma after the full approval of the treatment.